C
12.68
0.08 (0.63%)
| Previous Close | 12.60 |
| Open | 12.60 |
| Volume | 1,189,253 |
| Avg. Volume (3M) | 971,788 |
| Market Cap | 1,694,289,024 |
| Price / Sales | 103.12 |
| Price / Book | 4.36 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 |
| Operating Margin (TTM) | -205.18% |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 30.55% |
| Current Ratio (MRQ) | 14.37 |
| Operating Cash Flow (TTM) | -162.02 M |
| Levered Free Cash Flow (TTM) | -106.95 M |
| Return on Assets (TTM) | -28.58% |
| Return on Equity (TTM) | -74.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Centessa Pharmaceuticals plc | Bullish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.34% |
| % Held by Institutions | 96.61% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Index Venture Life Associates Vi Ltd | 31 Mar 2025 | 9,961,789 |
| General Atlantic, L.P. | 31 Mar 2025 | 9,681,818 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 38.00 (Piper Sandler, 199.69%) | Buy |
| Median | 32.50 (156.31%) | |
| Low | 28.00 (Guggenheim, 120.82%) | Buy |
| Average | 32.75 (158.28%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 13.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 28 May 2025 | 35.00 (176.03%) | Buy | 12.95 |
| Chardan Capital | 08 May 2025 | 30.00 (136.59%) | Buy | 12.39 |
| Piper Sandler | 31 Mar 2025 | 38.00 (199.68%) | Buy | 14.38 |
| Guggenheim | 26 Mar 2025 | 28.00 (120.82%) | Buy | 14.54 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |